Adjusted^* hazards ratio of the risk of tuberculosis among patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31, 2001 in a Cox proportional hazards model.

*<p>All two-way interactions were tested</p><p>Note: neither the term co-trimoxazole prophylactic treatment nor IPT were statistically significant in the final model</p

Kaplan-Meier survival curve* of the proportion of patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31, 2001 who remained TB free at primary study endpoint (i.e., TB, death, or last clinic visit) over the time course (in days) of the study period, by intervention (HAART, ART non-HAART), and non-intervention (ART naïve).

<p>Kaplan-Meier survival curve* of the proportion of patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31, 2001 who remained TB free at primary study endpoint (i.e., TB, death, or last clinic visit) over the time course (in days) of the study period, by intervention (HAART, ART non-HAART), and non-intervention (ART naïve).</p

List of the most commonly prescribed classes of and specific antiretroviral agents and their combinations used in HAART and ART non-HAART ART regimens among patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31, 2001.

*<p>A total of 36 unspecified ART regimens (HAART = 22 and ART non-HAART = 14) were cumulatively used for at least one day, 780 times during the study period^∼</p>**<p>See footnotes, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000826#pone-0000826-t001" target="_blank">Table 1</a></p>***<p>Protease inhibitors (includes ritonavir-boosted regimens)</p><p>^A total of 177 specific ART regimens were cumulatively used for at least one day, 1421 times during the study period^∼</p>∼<p>Note that the number of ART regimens cumulatively used during the study period exceeds the total study population because, for those on ART, more than one regimen may have been prescribed during the study period</p

Socio-demographic characteristics, by TB status, of patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31, 2001.

*<p>Denominators vary due to missing data in the patient medical record for each characteristic (missing values deleted from analysis)</p>**<p>Each subcategory (i.e., heterosexual and MSM) includes the subset of male patients who were reported as bisexual (n = 45 of 152 heterosexual males), and therefore, the sum of the numerators of both subcategories is greater than the denominator</p

Breakdown of study patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31, 2001 by intervention (HAART, ART non-HAART), and non-intervention (ART naïve).

<p>Breakdown of study patients attending public HIV treatment facilities in Brazil (n = 463) between January 1, 1995 and December 31, 2001 by intervention (HAART, ART non-HAART), and non-intervention (ART naïve).</p

Cumulative list of antiretroviral agents available in public HIV treatment facilities in Brazil between January 1, 1995 and December 31, 2001.

*<p>Nucleoside reverse transcriptase inhibitor</p>**<p>Non-nucleoside reverse transcriptase inhibitor</p

MOESM2 of Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

Additional file 2. Lengths of neutral microsatellite markers for late treatment failures and randomly chosen treatment successes, Angola therapeutic efficacy monitoring, 2015

MOESM1 of Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

Additional file 1. Kaplan–Meier estimates of the proportion of participants with adequate clinical and parasitological response (ACPR) over the course of follow up during therapeutic efficacy monitoring in Angola, 2015. AL: Artemether-lumefantrine, ASAQ: Artesunate-amodiaquine, DP: Dihydroartemisinin-piperaquine